348 related articles for article (PubMed ID: 35379201)
1. Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice.
Yamamoto T; Tsukita Y; Katagiri Y; Matsushita H; Umezawa R; Ishikawa Y; Takahashi N; Suzuki Y; Takeda K; Miyauchi E; Saito R; Katsuta Y; Kadoya N; Jingu K
BMC Cancer; 2022 Apr; 22(1):364. PubMed ID: 35379201
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the incidence of ≥ grade 2 radiation pneumonitis between intensity-modulated radiotherapy and three-dimensional conformal radiotherapy in patients with unresectable non-small cell lung cancer treated with durvalumab after concurrent chemoradiotherapy.
Masuo M; Shinohara E; Kitano M; Maruta R; Chonabayashi S; Endo S; Matumoto S; Nishiyama N; Machitori Y; Kobayashi M
Jpn J Clin Oncol; 2024 Mar; 54(3):312-318. PubMed ID: 38010609
[TBL] [Abstract][Full Text] [Related]
3. Clinical features and risk factors for interstitial lung disease spreading in low-dose irradiated areas after definitive radiotherapy with or without durvalumab consolidation therapy for patients with non-small cell lung cancer.
Sakagami M; Inokuchi H; Mukumoto N; Itoyama H; Hamaura N; Yamagishi M; Mukumoto N; Matsuda S; Kabata D; Shibuya K
Radiat Oncol; 2023 May; 18(1):87. PubMed ID: 37217919
[TBL] [Abstract][Full Text] [Related]
4. Intensity-modulated radiation therapy with concurrent chemotherapy followed by durvalumab for stage III non-small cell lung cancer: A multi-center retrospective study.
Tsukita Y; Yamamoto T; Mayahara H; Hata A; Takeda Y; Nakayama H; Tanaka S; Uchida J; Usui K; Toyoda T; Tamiya M; Morimoto M; Oya Y; Kodaira T; Miyauchi E; Jingu K; Sugiura H
Radiother Oncol; 2021 Jul; 160():266-272. PubMed ID: 34023330
[TBL] [Abstract][Full Text] [Related]
5. Intensity-Modulated Radiation Therapy May Improve Local-Regional Tumor Control for Locally Advanced Non-Small Cell Lung Cancer Compared With Three-Dimensional Conformal Radiation Therapy.
Wang J; Zhou Z; Liang J; Feng Q; Xiao Z; Hui Z; Wang X; Lv J; Chen D; Zhang H; Ji Z; Cao J; Liu L; Jiang W; Men Y; Xu C; Dai J; Yin W; Wang L
Oncologist; 2016 Dec; 21(12):1530-1537. PubMed ID: 27628491
[TBL] [Abstract][Full Text] [Related]
6. Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled Trial.
Tachihara M; Tsujino K; Ishihara T; Hayashi H; Sato Y; Kurata T; Sugawara S; Shiraishi Y; Teraoka S; Azuma K; Daga H; Yamaguchi M; Kodaira T; Satouchi M; Shimokawa M; Yamamoto N; Nakagawa K;
JAMA Oncol; 2023 Nov; 9(11):1505-1513. PubMed ID: 37676681
[TBL] [Abstract][Full Text] [Related]
7. Impact of interstitial lung abnormality on survival after adjuvant durvalumab with chemoradiotherapy for locally advanced non-small cell lung cancer.
Kashihara T; Nakayama Y; Okuma K; Takahashi A; Kaneda T; Katagiri M; Nakayama H; Kubo Y; Ito K; Nakamura S; Takahashi K; Inaba K; Murakami N; Saito T; Okamoto H; Itami J; Kusumoto M; Ohe Y; Igaki H
Radiother Oncol; 2023 Mar; 180():109454. PubMed ID: 36640944
[TBL] [Abstract][Full Text] [Related]
8. The efficacy profiles of concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab in patients with unresectable stage III non-small cell lung cancer: A multicenter retrospective cohort study.
Takeda Y; Kusaba Y; Tsukita Y; Uemura Y; Miyauchi E; Yamamoto T; Mayahara H; Hata A; Nakayama H; Tanaka S; Uchida J; Usui K; Toyoda T; Tamiya M; Morimoto M; Oya Y; Kodaira T; Jingu K; Sugiura H
Clin Transl Radiat Oncol; 2022 Nov; 37():57-63. PubMed ID: 36065360
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer.
Nishimura A; Ono A; Wakuda K; Kawabata T; Yabe M; Miyawaki T; Miyawaki E; Kodama H; Nishioka N; Mamesaya N; Kobayashi H; Omori S; Kenmotsu H; Naito T; Murakami H; Harada H; Takahashi T
Invest New Drugs; 2022 Apr; 40(2):403-410. PubMed ID: 34633575
[TBL] [Abstract][Full Text] [Related]
10. Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer.
Mayahara H; Uehara K; Harada A; Kitatani K; Yabuuchi T; Miyazaki S; Ishihara T; Kawaguchi H; Kubota H; Okada H; Ninomaru T; Shindo C; Hata A
Radiat Oncol; 2022 Jan; 17(1):7. PubMed ID: 35033139
[TBL] [Abstract][Full Text] [Related]
11. [Technical advancement improves survival in patients with locally advanced non-small cell lung cancer (LA-NSCLC) receiving definitive radiotherapy].
Wang JB; Jiang W; Ji Z; Cao JZ; Liu LP; Men Y; Xu C; Wang XZ; Hui ZG; Liang J; Lyu JM; Zhou ZM; Xiao ZF; Feng QF; Chen DF; Zhang HX; Yin WB; Wang LH
Zhonghua Zhong Liu Za Zhi; 2016 Aug; 38(8):607-14. PubMed ID: 27531481
[TBL] [Abstract][Full Text] [Related]
12. Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial.
Chun SG; Hu C; Choy H; Komaki RU; Timmerman RD; Schild SE; Bogart JA; Dobelbower MC; Bosch W; Galvin JM; Kavadi VS; Narayan S; Iyengar P; Robinson CG; Wynn RB; Raben A; Augspurger ME; MacRae RM; Paulus R; Bradley JD
J Clin Oncol; 2017 Jan; 35(1):56-62. PubMed ID: 28034064
[TBL] [Abstract][Full Text] [Related]
13. Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non-small cell lung cancer in comparison with chemoradiotherapy alone.
Abe T; Saito S; Iino M; Aoshika T; Ryuno Y; Ohta T; Igari M; Hirai R; Kumazaki Y; Miura Y; Kaira K; Kagamu H; Noda SE; Kato S
Thorac Cancer; 2021 Jan; 12(2):245-250. PubMed ID: 33289347
[TBL] [Abstract][Full Text] [Related]
14. Prospective multicenter cohort study of durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis.
Sugimoto T; Fujimoto D; Sato Y; Tamiya M; Yokoi T; Taniguchi Y; Hino A; Hata A; Uchida J; Fukuda Y; Hara S; Kanazu M; Matsumoto H; Kokubo M; Yamamoto N
Lung Cancer; 2022 Sep; 171():3-8. PubMed ID: 35863254
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of post-treatment C-reactive protein-to-albumin ratio in locally advanced non-small cell lung cancer patients receiving durvalumab after chemoradiotherapy.
Araki T; Tateishi K; Komatsu M; Sonehara K; Wasamoto S; Koyama S; Yoshiike F; Hama M; Nishie K; Kondo D; Agatsuma T; Kato A; Takata M; Kanda S; Hanaoka M; Koizumi T
Thorac Cancer; 2022 Jul; 13(14):2031-2040. PubMed ID: 35616056
[TBL] [Abstract][Full Text] [Related]
16. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial.
Faivre-Finn C; Vicente D; Kurata T; Planchard D; Paz-Ares L; Vansteenkiste JF; Spigel DR; Garassino MC; Reck M; Senan S; Naidoo J; Rimner A; Wu YL; Gray JE; Özgüroğlu M; Lee KH; Cho BC; Kato T; de Wit M; Newton M; Wang L; Thiyagarajah P; Antonia SJ
J Thorac Oncol; 2021 May; 16(5):860-867. PubMed ID: 33476803
[TBL] [Abstract][Full Text] [Related]
17. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
Antonia SJ; Villegas A; Daniel D; Vicente D; Murakami S; Hui R; Yokoi T; Chiappori A; Lee KH; de Wit M; Cho BC; Bourhaba M; Quantin X; Tokito T; Mekhail T; Planchard D; Kim YC; Karapetis CS; Hiret S; Ostoros G; Kubota K; Gray JE; Paz-Ares L; de Castro Carpeño J; Wadsworth C; Melillo G; Jiang H; Huang Y; Dennis PA; Özgüroğlu M;
N Engl J Med; 2017 Nov; 377(20):1919-1929. PubMed ID: 28885881
[TBL] [Abstract][Full Text] [Related]
18. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
Antonia SJ; Villegas A; Daniel D; Vicente D; Murakami S; Hui R; Kurata T; Chiappori A; Lee KH; de Wit M; Cho BC; Bourhaba M; Quantin X; Tokito T; Mekhail T; Planchard D; Kim YC; Karapetis CS; Hiret S; Ostoros G; Kubota K; Gray JE; Paz-Ares L; de Castro Carpeño J; Faivre-Finn C; Reck M; Vansteenkiste J; Spigel DR; Wadsworth C; Melillo G; Taboada M; Dennis PA; Özgüroğlu M;
N Engl J Med; 2018 Dec; 379(24):2342-2350. PubMed ID: 30280658
[TBL] [Abstract][Full Text] [Related]
19. Durvalumab impacts progression-free survival while high-dose radiation >66 Gy improves local control without excess toxicity in unresectable NSCLC stage III: Real-world data from the Austrian radio-oncological lung cancer study association registry (ALLSTAR).
Zehentmayr F; Feurstein P; Ruznic E; Langer B; Grambozov B; Klebermass M; Hüpfel H; Feichtinger J; Minasch D; Heilmann M; Breitfelder B; Steffal C; Gastinger-Grass G; Kirchhammer K; Kazil M; Stranzl H; Dieckmann K;
Radiother Oncol; 2024 Jul; 196():110294. PubMed ID: 38653380
[TBL] [Abstract][Full Text] [Related]
20. Early administration of durvalumab after chemoradiotherapy increased risk of pneumonitis in patients with locally advanced non-small cell lung cancer.
Harada D; Shimonishi A; Saeki K; Ninomiya T; Kanzaki H; Nagasaki K; Ogura C; Tsutsui Y; Kojin K; Hamamoto Y; Kozuki T
Asia Pac J Clin Oncol; 2023 Apr; 19(2):e111-e117. PubMed ID: 35686586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
